GLP-1 Weight-Loss Drugs Linked to Nutritional Deficiencies in Children

The growing use of GLP-1 weight-loss drugs among children and teenagers raises important questions about their nutritional health. In this study, researchers examined health insurance data for 2,031 young people aged 10 to 17 who were taking GLP-1 drugs. Within a year of starting treatment, 16.8 percent – almost one in six – had been diagnosed with at least one nutritional deficiency or related complication. Vitamin D deficiency was by far the most common, affecting 12.4 percent.

Despite this, nutritional support was surprisingly uncommon. Only 23.3 percent had received nutrition therapy or counseling within six months of starting treatment, and the average wait for a first consultation was almost five months. The study cannot establish that GLP-1 drugs themselves caused the deficiencies, and the researchers acknowledge that deficiencies may sometimes have been present but undiagnosed before treatment. Nevertheless, the findings suggest that nutritional monitoring is often not being properly integrated into the care of young people taking these drugs.

This is especially concerning because GLP-1 drugs work partly by suppressing appetite and reducing food intake. When growing children eat less, ensuring that the food they do consume supplies sufficient essential nutrients becomes particularly important. Medicine has known for decades that pharmaceutical drugs can contribute to nutritional problems, yet this issue still receives remarkably little attention. Prescribing powerful weight-loss drugs to children without simultaneously paying close attention to their micronutrient status risks treating one health problem while potentially contributing to others.

To read how GLP-1 weight-loss drugs have been linked to a brain condition that can cause permanent brain damage, see this news story on our website.